Check out: www.thailandstartup.news , www.thailandcondo.news , www.thailandhotel.news , www.thailandfintech.news , www.thailandblockchain.news , www.thailandbusiness.news , www.thailandit.news , www.thailandwellness.news & 4850 new sites.

Med News
Featuring latest Drug Developments and Treatment Protocols and also Updates about the Pharmaceutical Industry , both in Thailand and abroad, latest USFDA and Thai FDA approvals and also Corporate News with regards to various Pharma companies.
Presented by
Source: Thailand Medical News  Sep 02, 2019
Researchers  from Brigham Hospital and Greater Paris University Hospitals presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS), during the current European Society of Cardiology Congress 2019.The clinical trial  evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary art...
Source: Thailand Medical News  Aug 16, 2019
The US FDA announced this week the approval of pretomanid tablets as part of a 3 drug combo protocol for the treatment regimen for the most deadly strain of tuberculosis which is fast spreading globally with increasing occurrence rates. Pretomanid (PA-824) tablets were approved to be used as part of a three drug combination protocol along with bedaquiline and linezolid in patients with extensive ...
Source: Thailand Medical News  Aug 03, 2019
The European Commission on Ist Of August had granted marketing authorisation for two new methods of administering Nucala (mepolizumab): a pre-filled pen and a pre-filled safety syringe. This is the only monthly dose anti-IL5 biologic approved in Europe that patients with severe eosinophilic asthma can self-after getting it prescribed by a pulmonologists. The original lyophilised version remains av...
Source: Thailand Medical News  Jul 04, 2019
The US FDA has approved  a new drug, Selinexor to treat patients  with  relapsed or refractory multiple myeloma, overruling a panel of external cancer experts who expressed concerns about its toxicity. The FDA approval was under an accelerated, or conditional, approval based on a single-arm clinical trial showing a 25% tumor response rate. The patients enrolled in the clinical trial...
Source: Thailand Medical News  Jun 01, 2019
Vascepa ( Icosapent Ethyl) by Amarin Group Of Companies, (New Jersey, US) is the only EPA prescription Omega-3 clinically proven to lower very high triglycerides in adults by 33%, without raising bad cholesterol (LDL-C). Unlike VASCEPA, common Omega Oil  and fish oil supplements  are not pure EPA and most also contain DHA which can raise bad cholesterol. The produc...